Personalized Needs in Clostridium Difficile Infections (SPECIFY)
Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Medical world is nowadays witnessing a sudden increase of the incidence of infections by Clostridium difficile (DCI). This is due in part to the prolongation of survival of patients with major comorbidities like solid tumor malignancies and lymphomas but also to the widespread intake of proton pump inhibitors and of wide-spectrum antimicrobials. It is highly probable that isolates of C.define causing this pandemic are genetically different than isolates of the same species predominating 20 years ago. This hypothesis is developed based on data of the epidemiology of CDI: in old times administration of clindamycin and ampicillin were the main drivers of CDI; recent studies report fluoroquinolones, 2nd and 3rd generation cephalosporins and even vancomycin (i.e. a drug of choice for CDI) to be linked with the development of CDI.
One major hurdle in management of CDI is relapse; the risk of relapse is reported as 15-20% after the first episode; however it is geometrically increased to even 60-80% after the second episode. As a consequence, management of CDI becomes a major health problem.
Fidaxomicin is a novel compound active against species of C.dificille. Results of two recent double-blind, randomized, large scale clinical studies have shown that oral treatment for 10 days with fidaxomicin 200mg bid was non-inferior to oral treatment with vancomycin 125mg q6h. However, the risk of relapse after treatment with vancomycin was close to 25% and with fidaxomicin close to 15%. This difference was statistically significant in both trials outscoring the superiority of fidaxomicin over vancomycin for the management of CDI. Moreover, meta-analysis has shown a significant reduction in mortality by fidaxomicin.
Despite proven superiority, prescription of fidaxomicin is limited to few cases mostly due to high cost. In many countries prescription is restricted to cases of relapsing CDI. Clinical feeling coming both from post-marketing experience as well as from published evidence supports the use of fidaxomicin for cases with risk of death and overt risk of relapse. However, molecular analysis of the C.difficile pathogen cannot be used as a tool for the prediction of relapse since in relapse cases pathogens carry less than 2 single nucleotide variants of the initial isolate. SPECIFY is aiming to develop a score using both clinical and genetic and biomarker data that can efficiently discriminate patients at risk of severe CDI and at risk of relapse of CDI. This score can become in future a tool to discriminate patients at need for treatment with fidaxomicin instead of traditional treatment with metronidazole/vancomycin.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Athens, Hellas, 10676
- 5th Department of Internal Medicine, Evangelismos Athens General Hospital
-
Athens, Hellas, 11527
- 1st Department of Internal Medicine, "G.Gennimatas" General hospital
-
Athens, Hellas, 11527
- 1st Department of Internal Medicine, Laikon General Hospital
-
Athens, Hellas, 11527
- 3rd Department of Internal Medicine, Sotiria General Hospital
-
Athens, Hellas, 12462
- 4th Department of Internal Medicine, Attikon University Hospital
-
Athens, Hellas, 15126
- 2nd Department of Internal Medicine, Sismanogleion General Hospital
-
Magoula, Hellas, 10918
- 1st Department of Internal Medicine, Thriassio General Hospital
-
Magoula, Hellas, 10918
- 2nd Department of Internal Medicine, Thriasio General Hospital
-
Maroúsi, Hellas, 15123
- 2nd Department of Oncology, Mitera Hospital
-
Piraeus, Hellas
- Infections Unit Tzaneion General Hospital
-
Pátra, Hellas, 36504
- Department of Internal Medicine, Patras University Hospital
-
Thessaloniki, Hellas, 54248
- 1st Department of Internal Medicine, AHEPA University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age equal to or more than 18 years
- Both genders
- Diarrhea defined as at least 3 episodes of unformed stools in the last 24 hours according to the Bristol stool chart
- Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.
Exclusion Criteria:
1. No exclusion criteria exist
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Bare etui
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Clostridium difficile infection
Patients with Clostridium difficile-associated diarrhea for development of biomarkers
|
Blood sampling
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Definition of prognostic biomarker
Tidsramme: 12 months
|
Patients with positive score and unfavorable outcome.
Unfavorable outcome is defined as at least one of the following: a) number of patients with severe infection at disease onset; b) number of patients who progress into severe infection; c) number of patients with disease recurrence; and d) number of patients who die
|
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Athanasios Skoutelis, MD, Evangelismos Athens General Hospital
- Studiestol: Evangelos J Giamarellos-Bourboulis, MD, PhD, Attikon Hospital
- Hovedetterforsker: George Chrysos, MD, PhD, Tzaneion Piraeus General Hospital
- Hovedetterforsker: Styliani Symbardi, MD, PhD, Thriassio Elefsis General Hospital
- Hovedetterforsker: Zoi Alexiou, MD, PhD, Thriassio Elefsis General Hospital
- Hovedetterforsker: Kostantinos Syrigos, MD, PhD, Sotiria General Hospital
- Hovedetterforsker: George Daikos, MD, PhD, Laikon Athens General Hospital
- Hovedetterforsker: Panagiotis Gargalianos, MD, PhD, G.Gennimatas Athens General Hospital
- Hovedetterforsker: Malvina Lada, MD, PhD, Sismanogleion General Hospital
- Hovedetterforsker: Charalambos Gogos, MD, PhD, University Hospital of Patras
- Hovedetterforsker: Ilias Athanasiadis, MD, PhD, Mitera General Hospital
- Hovedetterforsker: Symeon Metallidis, MD, PhD, AHEPA Thessaloniki University Hospital
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CL01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .